The BLSA, CCS, CSHA were composed of predominately white participants, and the CHS cohort had African Americans recruited from three of the four counties in its catchment area. The distribution of ethnicity was not reported for FHS and MoVIES.
Diagnosis & Evaluation Methods
The interviewers ascertained exposure information by self-report. In all studies, there was an in-person structured interview except for the CSHA study, in which there was a self-administered questionnaire. All studies assessed probable and possible AD. The diagnosis of AD was made using DSM-III-R and NINCDS-ADRDA for the BLSA, CCS, CSHA, and MoVIES cohorts; for the CHS and FHS cohorts, the diagnosis of AD was made using DSM-IV and NINCDS-ADRDA. Expert clinicians of consensus conferences made the diagnoses after review of neurocognitive assessments, detailed clinical evaluations, neuroimaging, and laboratory tests.
For BLSA, participants under the age of 60 are followed-up and assessed for dementia every four years; participants aged 60-79 years are assessed every two years; and participants aged 80 and older are assessed annually. For CCS, follow-up dementia evaluations occurred approximately every three years since baseline. For CSHA, participants have undergone follow-up assessments every five years since enrollment, ending in 2001. For CHS, participants have undergone follow-up assessments for cognitive function annually. For FHS, participants have been assessed every two years for age-related cognitive outcomes since 1976. For MoVIES, participants were followed approximately every two years for dementia assessments until 2002.
Szekely, C. A., Green, R. C., Breitner, J. C., Ostbye, T., Beiser, A. S., Corrada, M. M., . . . Zandi, P. P. (2008). No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology, 70(24), 2291-2298. doi: 10.1212/01.wnl.0000313933.17796.f6